Fintel reports that on December 3, 2025, Roth Capital initiated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 453.85% Upside As of November 17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback